Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.98 |
| ▸ | MTOR | P42345 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | THPO | P40225 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29634865 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| Bromide SCHEMBL11496230 | 0.99 | DRD1 (0.98) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL4388800 | 0.99 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL29389918 | 0.99 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL29388918 | 0.99 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| Bromide SCHEMBL11101325 | 0.92 | DRD2 (0.98) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL11273914 | 0.90 | DRD2 (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| Bromide SCHEMBL16241874 | 0.89 | KDM4E (1.00) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL14510732 | 0.89 | DRD1 (0.82) | DRD1DRD2KDM4EMAPTLMNA | |
| SCHEMBL7329572 | 0.88 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| US-10781472-B2 | Systems and methods for determining cyclic nucleotide concentration and related pathway activation | PROMEGA CORPORATION (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | disclosed |
| US-20180340210-A1 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-11-29 | — | — | US | disclosed |
| US-10000792-B2 | Methods for cyclic nucleotide determination | PROMEGA CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2400029-A2 | Methods for cyclic nucleotide determination | Promega Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2392667-A2 | Assay for phosphodiesterases | Promega Corporation (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-1963366-A4 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1963366-A2 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORPORATION (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070172896-A1 | Methods for cyclic nucleotide determination | PROMEGA CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007067557-A2 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-4192872-A | ANTI -PARKINSONISM ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | DRD1 17/4885DRD2 14/4885KDM4E 2052/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | DRD1 17/4885DRD2 14/4885KDM4E 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.